Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “CTOR”

756 pharma patents match "CTOR" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 756
Index total 30,257
Page 1 / 32

Quick answer

This filtered view shows 756 pharmaceutical patents matching "CTOR" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

756 results for “CTOR” · 30,257 patents in full index Clear search

  1. US 12421280

    Insulin like growth factor binding protein bioactive peptide fragments

    Northwestern University · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  2. US 12416006

    Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Sep 16, 2025 · Expires Sep 11, 2045

    granted
  3. US 12415866

    Monoclonal antibody inhibitor of Factor XIIa

    Takeda Pharmaceutical Company Limited · Granted Sep 16, 2025 · Expires Sep 11, 2045

    granted
  4. US 12410442

    Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  5. US 12403164

    Lentiviral vector formulations

    BIOVERATIV THERAPEUTICS INC. · Granted Sep 2, 2025 · Expires Aug 28, 2045

    granted
  6. US 12403183

    Factor VIII polypeptide formulations

    BIOVERATIV THERAPEUTICS INC. · Granted Sep 2, 2025 · Expires Aug 28, 2045

    granted
  7. US 12398373

    Enhanced immune effector cells and use thereof

    Fate Therapeutics, Inc. · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  8. US 12391642

    Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors

    NIKANG THERAPEUTICS, INC. · Granted Aug 19, 2025 · Expires Aug 14, 2045

    granted
  9. US 12383618

    Expression vector delivery system and use thereof for inducing an immune response

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  10. US 12377068

    In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors

    Provectus Pharmatech, Inc. · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  11. US 12378558

    RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  12. US 12371747

    Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy

    BIOVERATIV THERAPEUTICS INC. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  13. US 12365887

    CRISPR-Cas effector polypeptides and methods of use thereof

    The Regents of the University of California · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  14. US 12364775

    Viral vectors for cancer therapy

    Krystal Biotech, Inc. · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  15. US 12338439

    Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  16. US 12331297

    Coagulation factor V (F5) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  17. US 12331307

    Modified immunization vectors

    ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  18. US 12324828

    Conjugates of a factor VIII moiety having an oxime-containing linkage

    Nektar Therapeutics · Granted Jun 10, 2025 · Expires Jun 5, 2045

    granted
  19. US 12312616

    CRISPR-Cas effector polypeptides and methods of use thereof

    The Regents of the University of California · Granted May 27, 2025 · Expires May 22, 2045

    granted
  20. US 12304969

    Factor XI A2 domain-binding antibodies and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted May 20, 2025 · Expires May 15, 2045

    granted
  21. US 12297186

    Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5

    AGOMAB SPAIN, S.L.U. · Granted May 13, 2025 · Expires May 8, 2045

    granted
  22. US 12290505

    Tissue factor-targeted antibody-drug conjugate

    SHANGHAI MIRACOGEN INC. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  23. US 12285472

    Self-antigen displaying nanoparticles targeting auto-reactive immune factors and uses thereof

    The Regents of the University of California · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  24. US 12275955

    Combining iPSC derived effector cell types for immunotherapy use

    Fate Therapeutics, Inc. · Granted Apr 15, 2025 · Expires Apr 10, 2045

    granted